Your enormous French biopharma company
has been leveraging the new technology in its operations.
And yes, there's drug discovery, but also what's so interesting, Paul, is
you're integrating it within the functionality of your business on a day
to day basis. Yeah.
Thank you. And it's a pleasure to be here.
We're really trying to do incredible things for patients and discover new
medicines. And, you know, they are being the great
disrupter and all of the excitement last year, the wow of large language models.
And this year for us, it's all about the how and how we can get our, you know,
the large amounts of our organization focused, whether you're in
a lab doing expert AI, whether using generative AI in a regulatory or tax
driven parts of our business, and importantly, snackable AI when we're
looking at really trying to get better decision intelligence for almost
everybody in the organization with the

sole intent of becoming much more
efficient, effective in delivering new medicines.
It's amazing, really. I love this Snackable A.I.
you're using play. It's a proprietary app, but I'm I'm
going to ask sort of how have you thought about which underlying large
language model you should look to how you integrate this?
Do you go to outsource? Do you build it from within pool?
Well, look, we're drug discoverers and developers.
We're not coders at heart. So we have this first of its kind
relationship now with open A.I., a partnership with formation bio,
translating that for us to make sure that we can be customizing large
language models to look at drug discovery, to try and drug undruggable
diseases to this point. And we're doing things that have really
never been done before. It's early days, but it's extremely
promising.

And remember, there's such a large
amount of diseases that don't have medicines available for them because we
simply have not had the computing power or the opportunity to deploy ourselves
and know just now where this next great revolution in science. It's such a
privilege, actually, to lead a company at this point.
As for play, a sort of snackable approach, we partnered with a small
startup out of Germany, Elite. They've been working with us.
They've grown with us, and that's, by the way, open for everybody.
We don't own it. We're happy to share it.
We want all boats to rise in healthcare, after all.
And so the more users, the more fund, the more accuracy, more chance of
discovering new medicines. So how have your talent reacted?
Because there's so much doom mongering that A.I.
is going to take hold of our jobs. Well, I think our approach has been how
to weaponize our people to do better.

You know, I don't know whether you're familiar with Waze, the driving app, but I see it very much like that. I got to get in the car, I got to start the engine and drive to the end of the street. And if Waze says I'm statistically more likely to have an easier journey turning left rather than turning right, I want that advice. That's crowdsource large data real-time. I want all people to feel they are amplified or multiplied to not of that in that event to the goal is not about less people. The goal is about putting out people to be more effective and to make better decision intelligence. That in itself gives us a great opportunity to do something incredible and we've only seen a huge appetite. That's why on any given day we have 18,000 people in our organization using the AI we make available. And I think that's pretty fantastic. Let's talk about doing the amazing.

The Incredible because we have just seen a push up in your share price on the day, and you've been reorientating this business of Sanofi and thinking about more R&D, about drug discovery and application. Look, some costly cases in the way that you have to experiment, do clinical trials. But they paid off today, and we think about the drug discovery when it comes to a key lung chronic lung disorder. Can you just tell us about what that means to the business? Well, in Europe, just yesterday, today we got approval for chronic obstructive pulmonary disease. COPD affects a huge number of people, third biggest killer. We're ready to go now in Europe to be able to provide an advanced therapy that will reduce the chance of going to hospital by a third. And that's a breakthrough when there's been so little innovation there. We aspire to be the world's leading immunology company, and that's partly

driven by moments like that, that we
live for in our industry. To do things that transform or protect
patients' lives, will prevent disease. You know, the reality is we're a very
proud, huge, big company, but we wanted to be at the forefront of science again.
And we've made some big bets, but appropriately so, to try and make sure
our science is some of the most exciting.
And it's first in class to best in class.
And to couple it with our conversation of earlier, the more we add AI, the more
we improve our decision intelligence, the more opportunity we have to do more
in that space. And I think that's what's catching the
excitement in our organization. And and we believe we're quite far
ahead. I mean, of course, we're very
responsible about how we use AI, but others are still hesitating.
We're taking our moment. But sometimes you need good data to feed
in to these large language models.

Poll: What about the data on viruses, such as well, bird flu at the moment here in the UK and the US? Indeed, there is a worry that the data isn't being good enough in the United States. Is that something that worries you when you need to be developing a new vaccine for that? Yeah. Look, I mean, it's we've been through one pandemic. I think we've learned a great deal about trying to have the best data. And I think we position ourselves to take advantage of those opportunities on behalf of society. Frankly, we played a part, small part in Covid, but we stand ready should we be asked the data and its legitimacy. You know, we often that data comes in through government channels, through health systems. You know, we work at real-time speed to make sure that we have the very best data available in terms of large language models and the rest of the

data sets, you know, we collaborate far
and wide. We have partnerships with Okin, with
Adam Wise, with SNC. We, we really are trying to make sure
that we have at our fingertips huge data sets to mean our accuracy and our
predictive capability is far ahead of the competition.
We won't get it right everywhere, but the data integrity of the absolute
fundamentals start in place. Our relationship with Openai and with
formation by, we're putting our own data at play to make sure that they can learn
from it to again or both should rise when health get to do good.
You're also selling off bits of health care because you're focusing in on the
R&D, the drug side, and maybe the consumer business goes for a hefty price
tag. You've been thinking about IPO and
you've been thinking about sale. How is that process going, Paul?
Well, we announced last October that we were going to become a pure play
biopharma.

You know, we want to double down on the
things we just talked about, and we have an incredibly successful and energized
consumer business. We feel that they feel, in fact, that
they can stand better on their own two feet and be independent, raise their own
capital, take on their own projects, and we want to support them in that. It's the
right thing to do. All capital should be allocated towards
discovering new medicines, and that should be about growing that business
fast in the market, which, by the way, they're doing very successfully.
We've declared that by as early as Q4 24, we'll be ready to go to separate
that business. We haven't said how we will do it, but I
think it's quite well known that, you know, we're talking to interesting
parties, certainly, and we have the capital markets
vehicles available to us too. So no, we're excited for them.
There's a huge amount of interest.

It's a great business, and we hope to create value for the patients, for stakeholders, and indeed for the people in the business. Q4 24 is pretty notable, given that we're in quite a politically uncertain time. We to Brit, sit here looking that there's going to be an election and people voting in the UK tomorrow. And then, of course, this weekend is all important for France. How is a leader of such a French giant? Are you feeling about the political risk of doing a deal in this market? Well, you look, you know, in terms of health care and being a leader of an incredibly important French company, you know, our first priority is to ensure that whoever governs, they provide a predictable, stable environment. Because researchers at ten, 15-year process. So, you know, we need to think long term. We hope that whoever leads the country will think long term.

We know the current government has been incredibly supportive of innovation and creating that ecosystem. We hope that that would continue. Of course, you know, there are people trying to understand what it means for the economy, much like for the change in government, if it's to come about in the UK. And and people want that predictability in the markets too. You know, we're a long-term player trying to do the right things for patients, trying to drug the undruggable. And we hope to partner with whoever's in power, of course, because we have to be ready to do our part for society. And and, you know, so far we believe that can continue.

Sanofi CEO on AI's Impact, Lung Disease Drug Clearance

Welcome to the Bloomberg Technology YouTube channel. Subscribe for original series and mini-docs on game-changing technologies, profiles on innovators, live conversations with experts, and breaking technology news & analysis from Bloomberg TV.

Sanofi CEO on AI's Impact, Lung Disease Drug Clearance

Sanofi CEO on AI's Impact, Lung Disease Drug Clearance

스크립트